David Hoang: Hey. Good morning. Thank you for the update and fitting me into the Q&A. So I just had a quick question on gross to net for Auvelity in coming quarters. Can you give us any sense of how quickly we should expect the GTN to improve over time? And would improvement correlate with the rate at which you can establish favorable coverage at major health insurance plans? I know you mentioned six months to nine months or six months to nine month window for that to generally take place. Is that fair to assume GTN should also improve over that time?
Nick Pizzie: Yes, David. Thanks. It’s Nick. I think that’s the guidance that we previously gave and we’re really staying to that. It’s hard to give any further quantitative guidance on GTN until we start seeing broad payer coverage and then we’ll be able to give a good sense of what the GTN and where the GTN rely. So several quarters from now, I think we’ll be able to give a better — give you a better sense of where GTNs will be.
David Hoang: Great. Thanks.
Operator: The next question is from the line of Yatin Suneja with Guggenheim Securities. Please proceed with your questions.
Eddie Hickman: Hey. Good morning and thanks for taking our questions. This is Eddie on for Yatin. Just a few from us. On AXS-12, can you just provide a little bit more detail on the timing of those data this year? And what you would need to see to give you confidence moving forward, especially with comparison to Sunosi? And then just a quick follow-up on the Auvelity inventory. How much of that 5.2 in reported revenue for the quarter was due to channel stocking? Thanks.
Herriot Tabuteau: You want to take the last question?
Nick Pizzie: Yeah. I haven’t quantified the actual amount related to specifically the inventory. But as I mentioned earlier on the question, it was roughly 2.5 weeks of future demand. So you can kind of ballpark with that is that 2.5 weeks, we do take GTN deductions on that. So even though it hasn’t been sold, it’s been sold to our distributor, haven’t sold to channel. So we are accruing based on the proceeds or what we expect January’s GTN would we follow on that.
Herriot Tabuteau: And with regards to the timing for AXS-12, we expect to have results from that trial in the first half of this year. So that’s the guidance. And I think you can figure out what the first half is, so that would lead through the end of June. Then in terms of what we would want to see, we want to see a positive trial. And this is a placebo-controlled study. So obviously, we want to see a positive trial that would give us two studies that demonstrate the efficacy of the product. And with regards to the comparison to Sunosi, the indications are different. So Sunosi approved to treat €“ if that’s a big time significant in patients with narcolepsy and AXS-12 studying or a few of cataplexy in patients with narcolepsy.
Lori Englebert: And Eddie, if I could just add, Herriot, if you don’t mind, just to help provide context there. For narcolepsy patients, 100% of all narcolepsy patients that were from excessive data sleepiness and it’s only estimated that about 70% suffer from cataplexy, just going to give you context in terms of the patient difference €“ the difference in patients.
Eddie Hickman: Got it. Thank you so much.
Operator: Our next question comes from the line of Graig Suvannavejh with Mizuho Securities. Please proceed with your questions.
